Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece,Archives of Osteoporosis

当前位置： X-MOL 学术 › Arch. Osteoporos. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece
Archives of Osteoporosis ( IF 3.1 ) Pub Date : 2022-06-28 , DOI: 10.1007/s11657-022-01126-5
Maria P Yavropoulou ₁ , Polyzois Makras ₂ , Kostas Athanasakis ₃ , Vasiliki-Kalliopi Bournia ₄ , Konstantinos Mathioudakis ₅ , Anastasios Tsolakidis ₅ , Eva Kassi ₁ , Gregory Kaltsas ₁ , Panagiota Mitrou ₆ , Petros P Sfikakis ₄

Affiliation

Summary

We used the Greek nationwide database to capture individuals on anti-osteoporotic treatment during 2019. From the estimated number of 683,679 osteoporotic individuals, only 42% were receiving treatment, with the total annual cost being almost one-tenth of the total cost of fractures. The treatment gap was significantly higher in males than in females.

Introduction

Based on the 2019 European scorecard (SCOPE), osteoporosis is diagnosed in an estimated 683,679 individuals in Greece, with the direct cost of incident fractures being €694.7 million, although further relevant real-world data are scarce.

Methods

The e-Government Center for Social Security Services prescription database, which covers almost 100% of the Greek population, was used to capture all individuals on anti-osteoporotic treatment during 2019.

Results

A total of 288,983 among 8,641,341 people, corresponding to 3.3% of the total adult Greek population, had filled at least one anti-osteoporotic prescription (6.0% and 0.36% for females and males, respectively). Prevalence of anti-osteoporotic treatment increased with age, from 0.15% in those younger than 50 to 8.6% in those older than 70 years. Oral bisphosphonates were more frequently prescribed (58.8%), followed by denosumab (39.4%). Alendronate was more frequently prescribed in males and in people younger than 60 years. Denosumab was more frequently prescribed in females and in people older than 60 years. Selective estrogen-receptor modulators, teriparatide, and parenteral bisphosphonates accounted for 1.1%, 1.0%, and 0.02% of all prescriptions, respectively. Orthopedic surgeons (39.6%), endocrinologists (19.6%), general practitioners (19%), and rheumatologists (9.3%) prescribed the vast majority of anti-osteoporotic regimens, with significant differences in prescription patterns. The annual cost of treatment per patient increased significantly with age, being on average €323.33.

Conclusions

Less than half of the estimated number of individuals with osteoporosis in 2019 in Greece received treatment, with the total annual cost being far less than the estimated cost of incident-fragility fractures. The impact of this undertreatment on related health care costs merits further investigation.

中文翻译：

基于 2019 年希腊全国真实世界数据的抗骨质疏松药物使用流行率和模式

概括

我们使用希腊全国数据库收集了 2019 年期间接受抗骨质疏松治疗的个体。从估计的 683,679 名骨质疏松个体中，只有 42% 正在接受治疗，每年的总费用几乎是骨折总费用的十分之一。男性的治疗差距明显高于女性。

介绍

根据 2019 年欧洲记分卡 (SCOPE)，希腊估计有 683,679 人被诊断出骨质疏松症，骨折事件的直接成本为 6.947 亿欧元，尽管缺乏更多相关的现实世界数据。

方法

社会保障服务电子政务中心处方数据库覆盖了几乎 100% 的希腊人口，用于捕获 2019 年期间接受抗骨质疏松治疗的所有个人。

结果

在 8,641,341 人中，共有 288,983 人（相当于希腊成年总人口的 3.3%）服用过至少一种抗骨质疏松处方（女性和男性分别为 6.0% 和 0.36%）。抗骨质疏松治疗的流行率随着年龄的增长而增加，从 50 岁以下的 0.15% 到 70 岁以上的 8.6%。口服双膦酸盐的处方更频繁 (58.8%)，其次是狄诺塞麦 (39.4%)。阿仑膦酸盐更常用于男性和 60 岁以下的人群。狄诺塞麦更常用于女性和 60 岁以上的人群。选择性雌激素受体调节剂、特立帕肽和肠外双膦酸盐分别占所有处方的 1.1%、1.0% 和 0.02%。整形外科医生 (39.6%)、内分泌科医生 (19.6%)、全科医生 (19%)、和风湿病学家 (9.3%) 开具了绝大多数抗骨质疏松治疗方案，处方模式存在显着差异。随着年龄的增长，每位患者每年的治疗费用显着增加，平均为 323.33 欧元。